Hinge Health, Inc.
Hinge Health provides digital care for joint and muscle conditions to self-insured employers, health plans, Medicare Advantage populations, and federal insurance plans. Its software platform uses AI-powered motion tracking, personalized exercise plans, a wearable electrical nerve stimulation device, and support from licensed physical therapists, physicians, and health coaches. Programs cover chronic and acute pain, women’s pelvic health, surgery preparation and rehabilitation, fall prevention, and prevention. HingeSelect connects members with in-person MSK providers, while HingeConnect supports targeted care and provider coordination. Hinge Health sells its platform to employers, health plans, and government entities through direct sales and partners, including health plans, pharmacy benefit managers, and third-party administrators. Contracts provide recurring revenue over their terms, and partners may receive administrative or marketing fees. The company is headquartered in San Francisco.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Mecklenburg Gabriel M.I. sold 200,000 shares of Hinge Health, Inc. (HNGE) at an average of $122.41 ($121.76–$125.50, $24.48M total) across 5 trades on 2026-11-11 under a Rule 10b5-1 trading plan.
Budge James (Chief Financial Officer) sold 35,907 shares of Hinge Health, Inc. (HNGE) at an average of $121.62 ($119.52–$123.34, $4.37M total) across 5 trades on 2026-11-10 under a Rule 10b5-1 trading plan.
Hinge Health reported 3Q 2026 revenue of $234.97M, up year-over-year, driven by member retention and growth. EPS was $0.66. Gross margin improved to 87% from 82%. Client base grew to 3,270. The company launched a Migraine Care Program and acquired Cylinder Health.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning HNGE (Hinge Health, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent HNGE coverage spans earnings, insider activity and financial news.
In the last 30 days, HNGE insiders filed 32 SEC Form 4 transactions — no purchases and 32 sales ($28.8M). The most active reporter was Robinson Elliott with 22 filings. 31% of those filings were made under pre-arranged Rule 10b5-1 plans.
Large insider sell signals possible concerns and may trigger short‑term price pressure.
The insider sale may signal reduced confidence and could pressure the stock lower.
Quarterly earnings beat expectations with revenue growth and margin expansion.
No ownership change; likely no price impact.
Guidance lift suggests stronger growth trajectory.
AlphAI scores every news story that mentions HNGE with an AI model for sentiment and relevance, and aggregates insider trades from Hinge Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mecklenburg Gabriel M.I. sold 200,000 shares of Hinge Health, Inc. (HNGE) at an average of $122.41 ($121.76–$125.50, $24.48M total) across 5 trades on 2026-11-11 under a Rule 10b5-1 trading plan.
Budge James (Chief Financial Officer) sold 35,907 shares of Hinge Health, Inc. (HNGE) at an average of $121.62 ($119.52–$123.34, $4.37M total) across 5 trades on 2026-11-10 under a Rule 10b5-1 trading plan.
Hinge Health reported 3Q 2026 revenue of $234.97M, up year-over-year, driven by member retention and growth. EPS was $0.66. Gross margin improved to 87% from 82%. Client base grew to 3,270. The company launched a Migraine Care Program and acquired Cylinder Health.
Robinson Elliott sold 0 indirectly-held shares of Hinge Health, Inc. (HNGE) across 12 trades over 2026-11-04 to 2026-11-05.
Hinge Health (HNGE) reported Q3 2026 revenue of $235M, with an 88% gross margin and $77M operating income. The company forecasted 2026 revenue of $879M-$881M and aims to launch an integrated GI program by summer 2027, according to management.
Hinge Health, Inc. reported Q3 Non-GAAP EPS of $0.71, exceeding estimates by $0.11, with revenue of $235B, a $234.78B beat. GAAP gross margin improved to 87% from 82% YoY, while Non-GAAP gross margin rose to 88% from 83%. According to the company.
Hinge Health, Inc. (HNGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hinge Health reports record third quarter 2026 financial results • Revenue increased 52% year-over-year to $235 million • Free cash flow of $113 million, representing a 48% free cash flow margin • 2026 revenue guidance midpoint raised to $880 million, reflecting 50%
Bank of America analysts highlighted Box Inc (BOX), Samsara Inc (IOT), and Hinge Health Inc (HNGE) as top application software stocks for Q3 earnings, citing AI opportunities and growth acceleration. BOX is their top pick, expected to deliver 12% constant currency growth. IOT is seen gaining enterprise market share, while HNGE is projected to exceed revenue growth estimates.
Stifel raised its price target for Hinge Health (HNGE) to $130 from $115, citing strong app growth in September 2026. The stock, trading at $111.52, has surged 152% in six months. Analysts, including Truist and BofA, maintain positive outlooks, projecting revenue growth and setting targets up to $112.
Budge James (Chief Financial Officer) sold 47,720 shares of Hinge Health, Inc. (HNGE) at an average of $103.13 ($101.53–$104.34, $4.92M total) across 4 trades on 2026-10-12 under a Rule 10b5-1 trading plan.
